Target intelligence / Profile preview

Enterovirus VP1 capsid protein (VP1)

Target
VP1
Molecular classification
Viral structural protein, Capsid protein
01

Overview

The Enterovirus VP1 capsid protein is a major structural protein that forms the icosahedral shell of viruses within the Enterovirus genus, including poliovirus, coxsackievirus, and rhinovirus (UniProt P03300). It is the most surface-exposed protein and plays a pivotal role in viral pathogenesis by mediating attachment to host cell receptors and facilitating the entry of the viral genome (PubMed: 25605940). VP1 contains a specialized hydrophobic pocket, often called the "canyon," which is critical for the structural stability and uncoating of the virus (PubMed: 17307109). This protein is a significant target for antiviral therapy, specifically for a class of drugs known as capsid binders, such as pleconaril and pocapavir (PubMed: 11850360, PubMed: 26150541). These inhibitors bind within the VP1 hydrophobic pocket, preventing the conformational changes necessary for the virus to release its RNA into the host cell. Furthermore, VP1 is highly immunodominant and serves as the primary basis for the serological and molecular classification of enterovirus strains (PubMed: 10430872). Mutations within the VP1 protein are frequently associated with the development of drug resistance, posing a challenge for therapeutic development (PubMed: 15105531).

Other names
Viral protein 1Capsid protein VP1VP1 proteinEnterovirus structural protein 1
02

Mechanism of action

Capsid binders occupy a hydrophobic pocket in the VP1 protein, which stabilizes the virion and prevents the uncoating and release of viral RNA (PubMed: 17307109). This interaction can also inhibit viral attachment to host receptors by preventing the necessary conformational changes for receptor engagement (PubMed: 11850360).

03

Biological functions

Viral entryHost cell receptor bindingViral assemblyGenome packagingAntigenic determinant
04

Disease associations

InfectionHand, foot, and mouth diseasePoliomyelitisMyocarditisAseptic meningitisAcute flaccid myelitisRespiratory tract infection
05

Safety considerations

Rapid emergence of drug resistance mutations in the VP1 hydrophobic pocket (PubMed: 15105531)Limited clinical efficacy in some human trialsNarrow spectrum of activity across different enterovirus serotypes
06

Interacting drugs

Pleconaril

5 more in the full profile.

07

Biomarkers

Viral RNA load (RT-qPCR)VP1 sequence-based genotypingAnti-VP1 antibodiesNeutralizing antibody titers

Beyond the preview

Go deeper on Enterovirus VP1 capsid protein (VP1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Enterovirus VP1 capsid protein (VP1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call